Physician profile
Justin C Graff
NPI 1427041664
$85,009.73
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $22K · 2021: $35K · 2022: $5,878 · 2023: $34.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $19,461.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19,253.86 | 2019-2022 | |
| Allergan, INC. | $14,753.11 | 2019-2022 | |
| Pfizer INC. | $12,705.50 | 2019-2020 | |
| Abbvie INC. | $8,064.84 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $4,013.69 | 2022 | |
| Biogen, INC. | $1,079.19 | 2019-2022 | |
| Acorda Therapeutics, INC | $529.57 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $503.00 | 2019 | |
| Livanova USA, INC. | $465.51 | 2019-2022 | |
| Genzyme Corporation | $461.10 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $354.08 | 2019-2022 | |
| Greenwich Biosciences, INC. | $269.07 | 2019-2021 | |
| Amgen INC. | $267.17 | 2019-2021 | |
| Lilly USA, LLC | $254.99 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Graff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.